

# Anti-Anterior gradient 3 [AGR3.2]

**Catalogue number:** 162064

**Sub-type:** Primary antibody

**Images:**

## Contributor

**Inventor:**

**Institute:** Moravian Biotechnology

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-Anterior gradient 3 [AGR3.2]

**Alternate name:**

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** Antibody created to detect the endogenous AGR3 protein (with weaker affinity than the Mouse anti- Anterior gradient 3 monoclonal antibody (AGR3.1]). Binding specificity: human AGR3 protein. Epitope QYSQALKKV (determined using pepscan)

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgG1 kappa

**Reactivity:** Human

**Selectivity:**

**Host:** Mouse

**Immunogen:** Purified human AGR3 protein

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:** B cell donor: Splenocytes from mouse immunised with purified AGR3 protein, fusion partner: SP2

**Formulation:**

**Recommended controls:**

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:**

## Target details

**Target:** Anterior gradient 3

**Target alternate names:**

**Target background:** AGR3 (Anterior Gradient 3) is a human homologue of the XAG-2 protein expressed in *Xenopus laevis*, which was identified in a study analyzing mRNA expression in ER-positive breast cancer-derived cell lines. The coding sequence of the AGR3 protein is located on the chromosome at position 7p21. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor ?)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers.

**Molecular weight:** Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.

**Ic50:**

## Applications

**Application:**

**Application notes:**

## Handling

**Format:** Liquid

**Concentration:**

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:**

**Storage conditions:**

**Shipping conditions:**

## Related tools

Related tools:

## References

References:

CancerTools.org